Introduction

Objective
• To make a short-term assessment in routine clinical practice of the efficacy and safety of Canagliflozin in patients with T2DM 
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• In clinical trials, the SGLT2 inhibitor Canagliflozin inhibits renal reabsorption of glucose, increases its excretion and reduces hyperglycaemia in patients with type 2 diabetes mellitus (T2DM).
• The increase in glucosuria and diuresis produced, results in a reduction in weight and blood pressure (BP). Moreover, it may cause genital and urinary tract infections.
• However, does Canagliflozin behave in the same way in routine clinical practice?
• .Thirty-three T2DM patients of 60.4±10.9 years of age and 13.6±7.3 years of evolution (12 women, 21 men), with BMI>30 Kg/m 2 , HbA1C>7% and estimated glomerular filtration rate> 60 ml/min, had Canagliflozin 100 mg/day added to their treatment in monotherapy (n=2), double therapy (n=6), triple therapy (n=7), oral antidiabetic drugs (OADS)+basal Insulin (n=5), OADS+basal bolus (n=10); OADS+rapid insulin (n=1) and basal bolus (n=2).
• They were weighed and HbA1C, fasting glucose (FG), systolic BP (SBP) and diastolic BP (DBP) were measured, before and 3 months after adding Canagliflozin.
• A p<0.05 was considered significant (SPSS, v. 20.0).
Figure 1.
Percentage of patients achieving A1c, weight and BP compound goals, 3 months after 100 mg / day of Canagliflozin Table 1 . Baseline characteristics of the 33 study subjects with T2DM. Table 2 . Weight, HbA1c and blood pressure before and after 3 months of taking a dose of 100 mg / day of canagliflozin in T2DM study patients.
• Baseline characteristics of patients are shown in Table 1 • At 3 months, weight (p<0.001), HbA1c (p=0.000), FG (p=0.000), and SBP (P<0,01) reduction were observed (Table 2 ).
• The average weight lost was 3.45±2.9 Kg., HbA1c was 1.13±0.83 %, and SBP was 7.7±8.6 mmHg (Table 3 ).
• 69.2% of patients achieving HbA1c< 7%, and decrease in weight and SBP (Figure 1 ).
• Only two genital infection and one urinary infection were observed, that evolved well, not requiring treatment discontinuation (Table 3) .
Conclusion
• In clinical practice and in the short-term, Canagliflozin added to the treatment of poorly controlled and obese T2DM patients, at any therapeutic level, was translated into a reduction in weight, HbA1c and SBP in more than 2/3 parts, with few adverse effects.
• Long-term studies with more number of patients should be conducted to find out whether the results are maintained.. 
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Genital infections 2/33 (6,1%) Table 3 . Mean weight loss, mean HbA1c, SBP and DBP reductions; and adverse events, 3 months after 100 mg / day of Canagliflozin in T2DM study patients
